All information provided in Connect is for information purposes only and does not constitute a legal relationship between Redox and any organization or entity unless otherwise specified.
LynxDx
Overview
Building the next generation of prostate cancer diagnostics
LynxDx is working to commercialize a prostate cancer urine diagnostic assay that is able to confidently prevent many unnecessary prostate biopsies. The test, called the MyProstateScore (MPS), is performed in a regulatory-compliant commercial laboratory.
To assist in the global response to the COVID-19 pandemic, LynxDx has worked aggressively to repurpose our clinical laboratory infrastructure to offer diagnostic COVID-19 testing, and is now Michigan’s largest provider of COVID-19 testing.
Find out more about LynxDx
Curious how you'd connect to a healthcare product like LynxDx?
Labs, genomics & precision medicine
Labs, genomics, and precision medicine healthcare products leverage genetic and molecular advances to enable personalized medicine. These tools analyze patient data to create customized treatment plans based on individual genetic, lifestyle, and environmental factors, improving the accuracy and speed of diagnosis and treatment. They enhance the quality of care delivery, reduce healthcare costs, and facilitate more targeted use of healthcare resources.
Explore all Labs, genomics & precision medicine powered by Redox
Can’t find what you’re looking for?
The information about healthcare organizations contained within this directory, including their names, websites, and descriptions, was accurate to the best of Redox’s knowledge as of the date of posting. Redox disclaims all warranties and representations, express or implied, regarding the information and services listed in this directory. Redox does not guarantee the accuracy of the information, nor does it endorse or recommend any particular provider or service. Users of this directory are solely responsible for verifying the accuracy and suitability of any information or service before relying on it.
